A meta-analysis of 6 studies 13,20,30,32,33,35 which attempted to estimate overall effect size of the changes from baseline in % FMD following GLP-1-based therapies could not find any significant difference between baseline and end-of-treatment samples (mean change from baseline was 0.83 [1.06, 2.73] %
Follow along as we explore the ins and outs of combining semaglutide and HRT
For all dosage references, see the peptide dosage chart
Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
If you manage both thyroid disease and weight or metabolic concerns, understanding how these medications interactand what baseline screening revealssupports more confident treatment decisions with your provider
Yes, but long-term success depends on more than just medication